Chorea News and Research

RSS

Researchers identify crucial player in controlling misfolded proteins

Researchers have identified a protein complex that marks misfolded proteins, stops them from interacting with other proteins in the cell and directs them towards disposal.

27 Mar 2019

Sleep disorders appear to be first sign of serious neurological diseases

Sleep disorders are often the first sign of serious neurological diseases. Neurologists should inquire extensively about the quality of their patients' sleep.

18 Jun 2018

New test methods with less fear

It is a principle of modern architecture that less may be more. This principle does not apply to information as a basis of far-reaching decisions, it seems.

21 Mar 2018

Newly discovered molecular chaperones may soon be part of therapies for Huntington's disease

Huntington's disease is a neurodegenerative disease. It is always fatal. The disease is caused by a defect in the Huntingtin gene. To this day, no therapy will put a stop to the insidious disintegration of brain cells.

12 Dec 2017

Dendritic-specific Golgi plays key role in early neuropathy of degenerative brain disease

A joint research team of DGIST have identified the early neuropathic mechanism of polyglutamine brain disease, one of the representative degenerative brain diseases, and suggested a way to restore.

10 Aug 2017

Research reveals new molecular mechanisms of Huntington's disease

The research just published by a group of scientists from the Centre for Genomic Regulation (CRG) in Barcelona, Spain, led by Eulàlia Martí, in cooperation with researchers from the University of Barcelona (UB) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), has brought to light new information on the molecular mechanisms that cause Huntington’s disease, and defines new pathways to therapy discovery.

8 Nov 2016

Computer-adaptive tests to measure health-related quality of life in Huntington's disease patients

Huntington's disease is an inherited disease that leads to problems with movement, thinking and mood which can negatively affect an individual's quality of life.

21 Oct 2016

New biomarker test helps detect autoimmune-induced neuropsychiatric disorders

A research team from the University of Oklahoma Health Sciences Center, led by Madeleine Cunningham, Ph.D., in conjunction with the National Institute of Mental Health, has developed the first-of-its-kind biomarker test to help detect autoimmune-induced neuropsychiatric disorders.

9 Sep 2016

Deutetrabenazine may help improve chorea symptoms in patients with HD

People with Huntington disease (HD) experienced improvements in chorea while taking deutetrabenazine (SD-809) compared to placebo, according to a paper published today in the Journal of the American Medical Association.

6 Jul 2016

Deuteration offers alternative chorea treatment for Huntington disease patients

Treatment with a deuterated form of tetrabenazine has resulted in improved motor signs among patients with Huntington disease, making it a potential treatment for chorea, trial findings show.

6 Jul 2016

Diseases that cause skin-related problems can also trigger serious neurological conditions

Diseases such as lupus that cause rashes and other skin problems also can trigger migraine headaches, strokes and other serious neurological conditions, according to an article by Loyola University Medical Center physicians.

16 Dec 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that NBI-98854, a highly selective small molecule VMAT2 inhibitor, showed a statistically significant reduction in tardive dyskinesia during the six weeks of placebo-controlled treatment in the Kinect 3 clinical trial. This Phase III trial included moderate to severe tardive dyskinesia patients with underlying schizophrenia, schizoaffective disorder, bipolar or major depressive disorder.

8 Oct 2015

Neurocrine completes enrollment in Phase III clinical trial of NBI-98854 in tardive dyskinesia patients

Neurocrine Biosciences, Inc. announced today that it has recently completed subject randomization of the Phase III clinical trial (Kinect 3 Study) of its proprietary Vesicular Mono-Amine Transporter 2 (VMAT2) compound NBI-98854 in tardive dyskinesia patients.

13 Aug 2015

Ruhr-Universität Bochum scientists develop mouse model to investigate SCA6

Scientists at the Ruhr-Universität Bochum established a mouse model for the human disease SCA6. SCA6 is characterised by movement deficits and caused by similar genetic alterations as Chorea Huntington. The mouse model will be used to investigate the disease mechanisms.

17 Jun 2015

Neurocrine reports net loss of $1.2 million for first quarter 2015

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $1.2 million, or $0.01 loss per share, compared to a net loss of $11.8 million, or $0.17 loss per share, for the same period in 2014.

30 Apr 2015

Neurocrine Biosciences, Mitsubishi Tanabe to develop and commercialize NBI-98854 in select Asian markets

Neurocrine Biosciences, Inc. today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation.

1 Apr 2015

Neurocrine Biosciences' NBI-98854 drug gets breakthrough designation for tardive dyskinesia

Neurocrine Biosciences, Inc. announced today that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation for its Vesicular Monoamine Transporter 2 inhibitor, NBI-98854, in tardive dyskinesia.

30 Oct 2014

Cedars-Sinai experts to present free conference on dystonia for patients, families and caregivers

A multidisciplinary team of experts affiliated with the Cedars-Sinai Movement Disorders Program will present a free conference for patients, families and caregivers on treatment options for dystonia, which causes painful and potentially crippling muscle contractions.

30 Sep 2014

Auspex enrolls first patient in SD-809 Phase 3 trial for treatment of chorea associated with HD

Auspex Pharmaceuticals announced today that the first patient has been enrolled in a multi-center Phase 3 pivotal trial of its lead investigational drug, SD-809 for the treatment of involuntary movements (chorea) associated with Huntington's Disease.

12 Jul 2013

HSG conducts clinical trial with novel drug formulation for treating Huntington disease

The Huntington Study Group (HSG), under the leadership of Samuel Frank, MD, Principal Investigator, (Boston University School of Medicine) and Claudia Testa, MD, PhD, co-Principal Investigator (Virginia Commonwealth University), is conducting a clinical trial with a formulation of the novel drug SD-809 in the treatment of HD the United States and Canada.

24 Jun 2013